Viewing StudyNCT05924880

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 7:11 PM
Last Modification Date: 2024-10-26 @ 3:02 PM
Study NCT ID: NCT05924880
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-25
First Post: 2023-06-01
Brief Title: A Phase 3b Open-label Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers BTC
Sponsor: AstraZeneca
Organization: AstraZeneca
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Biliary Tract Cancers
Keywords: